Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 3/20 | 0.40 |
| ▸ | CHUK | O15111 | 3/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27942660 | 0.87 | IKBKB (0.43) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL21315701 | 0.82 | AHR (0.48) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL4489425 | 0.80 | AHR (0.52) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL312307 | 0.78 | AHR (0.50) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL860074 | 0.78 | AHR (0.50) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL564695 | 0.78 | AHR (0.50) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL17064186 | 0.78 | AHR (0.50) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL14909105 | 0.78 | TNF (0.57) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL2599709 | 0.78 | AHR (0.45) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL13961694 | 0.78 | AHR (0.45) | AHRF7LTA4HF3NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114805664-A | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114292582-B | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114292582-A | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-104073045-A | Application of halogenated indole and derivatives thereof as marine antifouling agent | YANTAI INST COASTAL ZONE RES CAS | 2014-10-01 | — | — | CN | claimed |
| EP-4650345-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024215917-A1 | MITHRAMYCIN (MTM) 2' OXIMES | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024149242-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-4966977-A | PEROXIDATION OF INDOLE COMPOUND | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-10-30 | — | — | US | disclosed |
| CN-1042553-A | The preparation method of indigo compound | MITSUI TOATSU CHEMICALS (JP) | 1990-05-30 | — | — | CN | disclosed |
| EP-0368508-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-16 | — | — | EP | disclosed |
| CN-1037527-A | The preparation method of indigo compound | MITSUI TOATSU CHEMICALS (JP) | 1989-11-29 | — | — | CN | disclosed |
| EP-0339887-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0335524-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-10-04 | — | — | EP | disclosed |
| CN-1036025-A | The preparation method of indigo compound | MITSUI TOATSU CHEMICALS (JP) | 1989-10-04 | — | — | CN | disclosed |
| EP-0330419-A2 | Process for the preparation of indigo compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | AHR 2635/4885F7 4066/4885LTA4H 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.